|
|
 |
|
Viewing report
|
|
|
|
Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy Growth Surpassed by Generic Erosion
Datamonitor, July 2010, Pages: 220
2009 allergic rhinitis sales of $5 billion are estimated in the seven major markets, and forecasts a decline to $4.2 billion by 2019. The greatest threat to the market is generics, with drug classes having differing vulnerability to generic erosion. While the symptomatic treatment sales will decrease, immunotherapy sales are on the rise, with changing regulations dictating development.
Scope
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
- Assessment of key drug classes for allergic rhinitis, with analysis of impacting events and a 10 year sales forecast split by indication
- In-depth discussion of the role of immunotherapy in allergic rhinitis, with analysis of developments, regulations, and pipeline products
- Interactive patient-based forecasts of 3 immunotherapy products, with a discussion of their relative strengths and weaknesses
Highlights of this title
Datamonitor estimates 2009 allergic rhinitis sales in the seven major markets of $5 billion. This is forecast to drop to $4.2 billion in 2019, driven by the entrance of cheap generics, most notably in the US. Oral antihistamines are the more vulnerable to generic erosion, while nasal corticosteroids are partially protected by their device.
Reformulation of molecules and combinations are common, but timing is key. In 2009, Merck’s Clarinex (desloratadine) had a quarter of Claritin’s (loratadine) peak sales, having launched after generics. Meda Pharma’s azelastine follow-on has seen more success launching prior to patent expiry and Meda Pharma is now combining the drug with a steroid.
Changing regulations are driving development of immunotherapies, with large-scale development programs seen in recent years. While immunotherapy is expected to remain a niche market, significant growth is forecast. Two sublingual grass tablets, Grazax (ALK-Abelló) and Oralair (Stallergènes) forecast to have sales of $250m in the US and EU by 2019.
Key reasons to purchase this title
- Understand allergic rhinitis market trends, including life cycle management, current sales, and a 10 year sales forecast of symptomatic treatments
- Gain insight into the immunotherapy market and access patient based forecasts of three key immunotherapy products, with interactive assumptions
- Use analysis of key companies in the market and see how allergic rhinitis contributes to total brand sales
Customers who bought this item also bought
Product Profiles: Allergic Rhinitis - Heavily Genericized Market sees Areas of Innovation
Allergic Rhinitis Market Forecast
Prescribing Influences: Allergic Rhinitis - Treatment tolerability remains a key differentiator
R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipeline
Emerging Opportunities in Inhalation & Nasal Spray Generic Drugs 2010
Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Forecast Insight: HIV - Increasing dominance of fixed dose combinations raises bar for single agents
Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase
Commercial Insight: Opioids in Australia
|
|
|
|
